RNA-Seq Blog Transcriptome Research & Industry News
From OncLive by Jessica Hergert
The field of non–small cell lung cancer (NSCLC) has exploded with continuous advances in targeted therapies directed toward key molecular alterations, including rare mutations like MET exon 14 (METex14) skipping mutations, RET rearrangements, and ROS1 mutations, said Joel Neal, MD, PhD, who added that utilizing RNA-based next-generation sequencing (NGS) may show improved sensitivity compared with current testing methods.
“We’ve done a fantastic job in not only identifying targets that are driver oncogenes in lung cancer but also finding targeted therapies that work in those subsets of lung cancer,” said Neal, an associate professor of medicine (oncology) in the University Medical Line of the Department of Medicine-Oncology at Stanford University and a member of Stanford Cancer Institute.
“We also have had a lot of advances in testing technology, but we may identify more genetic targets through things like RNA[-based] NGS. In addition to DNA[-based] NGS, RNA[-based] NGS could be more sensitive in identifying rare targets, especially for gene rearrangements,” Neal added.
